Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congressional ‘Cures’ Debate Shifts To FDA Funding

This article was originally published in The Pink Sheet Daily

Executive Summary

House Democrats say FDA will need more money to be able to handle the responsibilities in the draft bill, while the agency worries reviews could slow without more resources.

You may also be interested in...



US FDA Getting More Money Up Front Under Cures Bill Revisions

Additional funding would arrive beginning in FY 2017 as House pushes bill to Senate.

Off-Label Communication Growth: Could FDA Afford To Police It?

Another user fee for the US drug agency could help pay for research of off-label uses, but lack of resources could be a regulatory problem.

Senate's Medical Innovation Bill Takes Cures' Shape

HELP Committee chairman finally calls his package a companion to 21st Century Cures bill, but more work is necessary to bring it in line with the House legislation.

Related Content

Topics

UsernamePublicRestriction

Register

PS078433

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel